Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
...ue high affinity and selective antagonists for the crf1 receptor that are currently in clinical developmen...e study to evaluate the safety and efficacy of the crf1 receptor antagonist, 876008, in approximately 130 ...8 and placebo. GSK has advanced a novel lead crf1 receptor antagonist compound, 561679, into a Phase...Neurocrine Biosciences Reports First Quarter 2008 Results
...ailable in the second half of 2008. GSK is also advancing the second lead crf1 receptor antagonist, 561679, into a Phase II major depression disorder study in the middle of this year. GSK has also moved a third crf1 compound, 586529, into a Phase I single dose escalating clinical trial. U...Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
...e II "proof of concept" clinical trial with a lead crf1 receptor antagonist compound, 876008, for SocAD an...e study to evaluate the safety and efficacy of the crf1 receptor antagonist compound in patients with SocA...d half of 2008. GSK is advancing the second lead crf1 receptor antagonist, 561679, into a Phase II depre...Neurocrine Biosciences Reports First Quarter 2009 Results
...ue high affinity and selective antagonists for the crf1 receptor that are currently in clinical developmen...ood disorders. GSK has advanced a novel lead crf1 receptor antagonist compound, 561679, into a Phase... dose-escalating clinical trial with an additional crf1 compound, 586529, for the treatment of anxiety and...Neurocrine Biosciences Reports Third Quarter 2008 Results
...ble later in 2008. GSK has advanced a novel lead crf1 receptor antagonist compound, 561679, into a Phase...single dose-escalating clinical trial with a third crf1 compound, 586529, for the treatment of anxiety and...itable for further clinical studies; risk that the crf1 receptor antagonist candidate's Phase II proof of ...Neurocrine Biosciences Reports Second Quarter 2008 Results
...of 2008. GSK will soon be advancing a novel lead crf1 receptor antagonist compound, 561679, into a Phase...single dose-escalating clinical trial with a third crf1 compound, 586529, for the treatment of anxiety and...itable for further clinical studies; risk that the crf1 receptor antagonist candidate's Phase II proof of ...